Utilization of sentinel lymph node mapping to determine pathologic outcomes for patients receiving neoadjuvant chemotherapy for locally advanced breast cancer

Editorial

Kirby I Bland. Ann Surg Oncol. 2002 Apr.

. 2002 Apr;9(3):217-9.

doi: 10.1007/BF02573056.

No abstract available

Comment on

A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. Newman LA, et al. Ann Surg Oncol. 2002 Apr;9(3):228-34. doi: 10.1007/BF02573059. Ann Surg Oncol. 2002. PMID: 11923128 Clinical Trial.
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.
Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Stearns V, et al. Ann Surg Oncol. 2002 Apr;9(3):235-42. doi: 10.1007/BF02573060. Ann Surg Oncol. 2002. PMID: 11923129
Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma.
Miller AR, Thomason VE, Yeh IT, Alrahwan A, Sharkey FE, Stauffer J, Otto PM, McKay C, Kahlenberg MS, Phillips WT, Cruz AB Jr. Miller AR, et al. Ann Surg Oncol. 2002 Apr;9(3):243-7. doi: 10.1007/BF02573061. Ann Surg Oncol. 2002. PMID: 11923130